SLC5A2 and kidney disorder: Patients with existing heart or kidney disease may benefit from starting SGLT-2 inhibitors therapy, while those with a higher risk of developing these conditions, such as obese patients and those with no cardiogenic stroke, may benefit more from GLP-1 RAs.